Construction and Validation of a Potent Epigenetic Modification-Related Prognostic Signature for Osteosarcoma Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background. Increasing evidence has shown that tumorigenesis correlates with aberrant epigenetic factors, such as DNA methylation, histone modification, RNA m6A modification, RNA binding proteins, and transcription factors. However, it is unclear that how epigenetic genes linked with alteration contribute to osteosarcoma’s incidence and clinical prognosis. We developed an epigenetic modification-related prognostic model that may improve the diagnosis and prognosis of osteosarcoma. Methods. We investigated the epigenetic modification-associated genes and their clinical significance in osteosarcoma in this research. Our gene transcriptome data were obtained from the TARGET database and the GEO database. Bioinformatics techniques were used to investigate their functionalities. The diagnostic and prognostic models were constructed using univariate and multivariate Cox regression. In addition, we developed a nomogram indicating the practicability of the prognostic model described above. Results. A risk score model constructed based on four epigenetic modification-related genes (MYC, TERT, EIF4E3, and RBM34) can effectively predict the prognosis of patients with osteosarcoma. Based on the risk score and clinical features, we constructed a nomogram. Conclusion. Epigenetic modification-related genes have been identified as important prognostic markers that may assist in osteosarcoma therapy therapeutic decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 6×
“We used Gene Set Enrichment Analysis (GSEA) [20] in the TARGET dataset to examine differences between high-and low-risk patients identified by prognostic models consisting of EMGs.”
MethodInfluentialSzklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1074 · Cited by 8,056 · cited 1×
“We used Cytoscape software to analyze a PPI network with 531 nodes and 2941 edges constructed from the STRING database [22] (Figure 4(a)) to investigate the function of differentially expressed EMGs in osteosarcoma.”
MethodThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340 · cited 1×
“Many elements of epigenetic alteration controlling gene expression that interfere with tumor development have been discovered by scientists in recent decades [23, 24].”
BackgroundReinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1370 · Cited by 887 · cited 1×
“gov/cellminer) [21], which includes 60 different cancer cell lines from nine different malignancies.”
BackgroundCistrome: an integrative platform for transcriptional regulation studies
Liu, T., Ortiz, J. A., Taing, L., Meyer, C. A., Lee, B., Zhang, Y., Shin, H., Wong, S. S., Ma, J., Lei, Y., et al. (2011) · Genome Biology · doi:10.1186/gb-2011-12-8-r83 · Cited by 716
Update on Survival in Osteosarcoma
Anderson, M. E. (2016) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2015.08.022 · Cited by 560
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
Molecular Biology of Osteosarcoma
Czarnecka, A. M., Synoradzki, K., Firlej, W., Bartnik, E., Sobczuk, P., Fiedorowicz, M., Grieb, P., & Rutkowski, P. (2020) · Cancers · doi:10.3390/cancers12082130 · Cited by 336 · cited 1×
“Introduction &e most frequent primary malignant bone tumor is osteosarcoma, which is primarily caused by primitive malignant bone mesenchymal cells [1, 2].”
BackgroundDNA methylation: TET proteins—guardians of CpG islands?
Williams, K., Christensen, J., & Helin, K. (2012) · EMBO reports · doi:10.1038/embor.2011.233 · Cited by 314
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
Cancer Epigenetics: An Introduction
Kanwal, R., Gupta, K., & Gupta, S. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-1804-1_1 · Cited by 259 · cited 1×
“Epigenetics is a concept that refers to dynamic and heritable alterations in different DNA sequences [12].”
BackgroundOsteosarcoma: Accelerating Progress Makes for a Hopeful Future
Saraf, A. J., Fenger, J. M., & Roberts, R. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00004 · Cited by 237
The mRNA cap-binding protein eIF4E in post-transcriptional gene expression
von der Haar, T., Gross, J. D., Wagner, G., & McCarthy, J. E. G. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb779 · Cited by 233 · cited 1×
“Typically, these transcripts encode proteins associated with proliferation, survival, invasion, and metastasis [33, 34].”
BackgroundGraff, J. R., & Zimmer, S. G. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1022943419011 · Cited by 215 · cited 1×
“EIF4E is a powerful oncogene that is found in about 30% of human malignancies [31, 32].”
BackgroundTopisirovic, I., Guzman, M. L., McConnell, M. J., Licht, J. D., Culjkovic, B., Neering, S. J., Jordan, C. T., & Borden, K. L. B. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.8992-9002.2003 · Cited by 206 · cited 1×
“EIF4E is a powerful oncogene that is found in about 30% of human malignancies [31, 32].”
BackgroundThe Roles of Human DNA Methyltransferases and Their Isoforms in Shaping the Epigenome
Gujar, H., Weisenberger, D. J., & Liang, G. (2019) · Genes · doi:10.3390/genes10020172 · Cited by 197
Čuljković, B., Topisirović, I., & Borden, K. L. B. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3688 · Cited by 181
Combining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J., Roberts, P., & Chiappinelli, K. B. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 160 · cited 1×
“Many elements of epigenetic alteration controlling gene expression that interfere with tumor development have been discovered by scientists in recent decades [23, 24].”
BackgroundNutrigenomics: Epigenetics and cancer prevention: A comprehensive review
Nasir, A., Bullo, M. M. H., Ahmed, Z., Imtiaz, A., Yaqoob, E., Safdar, M., Ahmed, H., Afreen, A., & Yaqoob, S. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1571480 · Cited by 159 · cited 1×
“Abnormalities in epigenetics may affect expression regulation and influence the balance of expression of oncogenes, leading to tumor development [13].”
BackgroundHIstome--a relational knowledgebase of human histone proteins and histone modifying enzymes
Khare, S., Habib, F., Sharma, R., Gadewal, N., Gupta, S., & Galande, S. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1125 · Cited by 158
Verrecchia, F., & Rédiní, F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00133 · Cited by 144 · cited 1×
“Patients with chemotherapy drug-resistant and lung metastatic osteosarcoma have a poor prognosis, with a 5-year survival rate of only 20% [5].”
BackgroundBeaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 128
A Time for MYC: Metabolism and TherapyPreprint
Dang, C. V. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031153 · Cited by 78
Immune-related prognosis biomarkers associated with osteosarcoma microenvironment
Hong, W., Yuan, H., Gu, Y., Liu, M., Ji, Y., Huang, Z., Yang, J., & Ma, L. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1165-7 · Cited by 77 · cited 1×
“Osteosarcoma has received a great deal of attention recently, including the use of biomolecules and risk models to assess the prognosis [9, 10].”
BackgroundHigh-throughput system-wide engineering and screening for microbial biotechnology
Vervoort, Y., Linares, A. G., Roncoroni, M., Liu, C., Steensels, J., & Verstrepen, K. J. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.02.011 · Cited by 74 · cited 1×
“High-throughput sequencing technologies, gene chips, and large-scale RNA-seq transcriptome sequencing have been widely used to identify genes associated with various cancers, elucidate carcinogenesis, and improve cancer treatment [7, 8].”
BackgroundOptimizing molecular signatures for predicting prostate cancer recurrence
Sun, Y., & Goodison, S. (2009) · The Prostate · doi:10.1002/pros.20961 · Cited by 73
Profiling and bioinformatics analyses reveal differential circular RNA expression in ovarian cancer
Wang, J., Wu, A., Yang, B., Zhu, X., Teng, Y., & Ai, Z. (2019) · Gene · doi:10.1016/j.gene.2019.144150 · Cited by 60 · cited 1×
“High-throughput sequencing technologies, gene chips, and large-scale RNA-seq transcriptome sequencing have been widely used to identify genes associated with various cancers, elucidate carcinogenesis, and improve cancer treatment [7, 8].”
BackgroundPathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Schick, M., Habringer, S., Nilsson, J. A., & Keller, U. B. (2017) · British Journal of Haematology · doi:10.1111/bjh.14917 · Cited by 47
Wen, J.-J., Ma, Y.-D., Yang, G.-S., & Gm, W. (2017) · PubMed · Cited by 42
Sánchez-Díaz, P. C., Hsiao, T.-H., Zou, Y., Sugalski, A., Heim-Hall, J. M., Chen, Y., Langevin, A., & Hung, J. Y. (2014) · Oncoscience · doi:10.18632/oncoscience.85 · Cited by 28
Avnet, S., Chano, T., Massa, A., Bonuccelli, G., Lemma, S., Falzetti, L., Grisendi, G., Dominici, M., & Baldini, N. (2019) · PubMed Central · Cited by 23
Rosemann, M., González-Vasconcellos, I., Domke, T., Kuosaite, V., Schneider, R., Kremer, M., Favor, J., Nathrath, M., & Atkinson, M. J. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-182 · Cited by 17 · cited 1×
“In addition, patients with the same clinical or pathological conditions receiving the same treatment protocol have different clinical outcomes due to their genetic heterogeneity [6].”
BackgroundRBPTD: a database of cancer-related RNA-binding proteins in humans
Li, K., Guo, Z., Zhai, X.-M., Yang, X., Wu, Y.-S., & Liu, T. (2020) · Database · doi:10.1093/database/baz156 · Cited by 16
Cited by
Epigenetic Changes Associated with Osteosarcoma: A Comprehensive Review
Twenhafel, L., Moreno, D., Punt, T., Kinney, M., & Ryznar, R. J. (2023) · Cells · doi:10.3390/cells12121595 · Cited by 38
“[73,74] TARGET database Prognostic Model EMGs and lncRNA levels used to assess patient prognosis and the 5-year survival rate”
BackgroundMethodYang, W., Zhang, M., Zhang, T.-X., Liu, J.-H., Hao, M.-W., Yan, X., Gao, H., Lei, Q.-Y., Cui, J., & Zhou, X. (2024) · JCI Insight · doi:10.1172/jci.insight.178535 · Cited by 31
Systemic strategies for osteosarcoma: advances and future directions
Morya, V. K., Magar, A. G., Park, S., & Noh, K.-C. (2025) · Discover Oncology · doi:10.1007/s12672-025-02208-9 · Cited by 32
Recent advances of m6A methylation in skeletal system disease
Liang, J., Yi, Q., Liu, Y., Li, J., Yang, Z., Sun, W., & Sun, W. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04944-y · Cited by 25
“Increasing evidences have reported that m6A regulators can act as prognostic biomarkers of OS [202].”
BackgroundZheng, D., Wei, Z., & Guo, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.849789 · Cited by 15
Metadata
- Authors
- Liu, S., Wu, B., Li, X., Zhao, L., Wu, W., & Ai, S.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Corresponding author
- Ai, Songtao
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2021-11-22
- Volume
- 2021
- Pages
- 1-14
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- PMC
- PMC8629625
- OpenAlex
- W3215576535
- Cited by
- 15
- References
- 35
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- osteosarcoma, epigenetic modifications, prognostic signature, risk scoring, nomogram, c-Myc, telomerase reverse transcriptase, EIF4E3, DNA methylation, histone modifications, m6A RNA methylation, RNA-binding proteins, transcription factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.